Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824135 | 0.82 | CYP2A6 (0.63) | CYP2A6APPSMN1; SMN2CYP2C9HDAC2 | |
| SCHEMBL1233284 | 0.82 | CYP2A6 (0.63) | TDP1KEAP1NFE2L2CYP2A6AKR1B1 | |
| SCHEMBL7827157 | 0.79 | AKR1B1 (0.67) | TDP1AKR1B1MAPT | |
| SCHEMBL18049795 | 0.79 | AKR1B1 (0.42) | TDP1KEAP1NFE2L2AKR1B1CYP2C9 | |
| SCHEMBL27320554 | 0.78 | CYP2A6 (0.44) | CYP2A6APPSMN1; SMN2CYP2C9MAPT | |
| SCHEMBL10339723 | 0.78 | CYP2A6 (0.53) | TDP1KEAP1NFE2L2CYP2A6AKR1B1 | |
| Acetic Acid SCHEMBL7564503 | 0.78 | CYP2A6 (0.58) | TDP1KEAP1NFE2L2CYP2A6SMN1; SMN2 | |
| SCHEMBL4381193 | 0.75 | CYP2A6 (0.54) | CYP2A6APPCYP2C9HDAC2HDAC3 | |
| SCHEMBL13356585 | 0.75 | CNR2 (0.48) | APPCYP2C9HDAC2HDAC3HDAC4 | |
| SCHEMBL27984156 | 0.74 | CNR2 (0.43) | CYP2A6APPSMN1; SMN2CYP2C9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| EP-2024371-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134434-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | TDP1 1492/4885KEAP1 227/4885NFE2L2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.